Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Three studies should shift thinking about the causes of inflammatory bowel disease. It seems that researchers have been focusing on the wrong cytokine as a driving force.
The retinoblastoma gene (RB) was the first tumor suppressor gene cloned. But, until recently, little clinical progress had been made to target human tumors deficient in RB function. A new approach emerges from studying retinoblastoma tumors.
A class of cell-killing chemotherapeutic agents seems to have an additional benefit. The drugs help prompt the immune system to turn against the tumor (pages 54–61).